SRA

Performing ChIP-seq analyses in clinical specimens has remained largely challenging due to multiple technical limitations and low quantities of starting material, resulting in low enrichments and poor signal-to-noise ratio. Here, we refined the original protocols for transcription factor ChIP-seq analyses in breast, prostate, and endometrial tumor tissue. In addition to the standard fixative formaldehyde, a second crosslinker Disuccinimidyl glutarate (DSG) was included in the procedure. Overall design: AR, FOXA1, ERa, H3K27ac & H3K4me3 ChIP-seq data with and without double croslinking in celllines (LNCAP & MCF-7) and in human tissues (Prostate, Breast, Endometrium and Prostate samples from core needle biopsies).